Universal opposition to EU pharmacovigilance fee plan
This article was originally published in SRA
Executive Summary
The European Commission is used to hearing mixed views on draft pharmaceutical legislation: after all, that is what the EU consultation and legislative procedures are for. But it must have been taken aback by the results of a recent public consultation on its planned pharmacovigilance fee system that found the "vast majority" of stakeholders did not support the proposal in its current form1.